Abiopharma

🔍 Bourdon David (Executive)

Company: LifeStance Health Group, Inc. (LFST)

Report Date: 2026-03-05

Detailed Transactions and Holdings:

• Acquired 395,683 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: false | shares_owned_after: 1,283,922.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 65,837 shares of Common Stock at $6.93 per share (Direct)
  Date: 2026-03-06 | Code: F | equity_swap_involved: false | shares_owned_after: 1,218,085.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Includes 395,683 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• F2: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of RSUs that vested on March 6, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested RSUs and do not constitute any open-market sale.